Pacritinib for hard-to-treat chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate or severe chronic GVHD after an allogeneic stem cell transplant
- Your cGVHD has not responded to at least two prior types of whole-body (systemic) medicines
- You are 18 years or older, and you can do daily activities at least at a moderate level (Karnofsky score 60% or higher)
- Your blood counts and key organ tests are strong enough (including minimum white blood cells, platelets, and liver/kidney function)
- If you are on cGVHD medicine right now, your dose must be stable or tapering for at least the past 4 weeks
- You can sign informed consent and, if pregnancy is possible for you (or you can father a child), you agree to highly effective birth control during the study and for at least 30 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.